Skip to main content

Table 1 (abstract P21). Primary and secondary outcome measures in erenumab-treated responder and nonresponder subgroups in STRIVE

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

Erenumab 70 mg Responders (n=135),
baseline
Responders,
change
Non responders (n=161), baseline Non responders change Overall
(n=312),
baseline
Overall,
change (mean±SE)
MMD 8.3 ±2.5 −6.1 ±2.1 8.3 ±2.4 −1.1 ±2.8 8.3 ±2.5 −3.4 ±0.2
MSMD 2.9 ±3.3 −2.0 ±2.4 3.8 ±3.5 −0.4 ±2.0 3.2 ±3.4 −1.1 ±0.1
MPFID-EA 13.5 ±8.5 −9.9 ±6.8 14.1 ±8.9 −2.4 ±7.0 14.0 ±8.9 −5.8 ±0.5
MPFID-PI 11.8 ±9.3 −8.4 ±7.00 12.7 ±9.6 −1.1 ±7.7 12.6 ±9.7 −4.4 ±0.5
Erenumab 140 mg Responders (n=159),
baseline
Responders,
change
Non responders (n=143), baseline Non responders change Overall
(n=318),
baseline
Overall,
Change (mean±SE)
MMD 8.2 ±2.4 −6.0 ±2.1 8.5 ±2.5 −1.4 ±2.3 8.3 ±2.5 −3.8 ±0.2
MSMD 3.2 ±3.4 −2.3 ±2.6 3.6 ±3.5 −0.9 ±1.7 3.4 ±3.5 −1.6 ±0.1
MPFID-EA 12.6 ±7.9 −8.9 ±6.8 13.6 ±8.6 −2.5 ±7.0 13.0 ±8.2 −5.8 ±0.4
MPFID-PI 11.5 ±8.3 −7.6 ±7.0 12.8 ±9.7 −1.8 ±8.00 12.0 ±9.0 −4.8 ±0.5
  1. Data are mean ±standard deviation, except as indicated.
  2. MMD monthly migraine days, MSMD migraine-specific medication treatment days, MPFID-EA Migraine Physical Function Impact Diary domain scores for everyday activity, MPFID-PI MPFID-physical impairment, SE standard error